Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Artiva Biotherapeutics Readies for the Next Phase of Growth with the Appointment of Neha Krishnamohan as CFO and EVP, Corporate Development and Promotion of Jennifer Bush to Chief Operating Officer
Read Article
News
2024
2023
Archive
Search news articles
April 12, 2024
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
March 21, 2024
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
March 20, 2024
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
March 11, 2024
Skye Bioscience Announces $40 Million Private Placement Equity Financing
March 7, 2024
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
February 27, 2024
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
February 27, 2024
Dianthus Therapeutics Announces Initiation of Phase II Magic Trial of DNTH103 in Generalized Myasthenia Gravis (GMG)
February 23, 2024
Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis
February 20, 2024
NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors
February 14, 2024
Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines
« Previous Page
1
2
3
4
…
119
Next Page »